Shore ND - Search Results

1

Updates on Management of Biochemical Recurrent Prostate Cancer.

Cooley LF, Srivastava A, Shore ND. Cooley LF, et al. Among authors: shore nd. Curr Treat Options Oncol. 2024 Mar;25(3):284-292. doi: 10.1007/s11864-023-01164-2. Epub 2024 Jan 3. Curr Treat Options Oncol. 2024. PMID: 38286895 Review.

2

Management of advanced prostate cancer - role of the urologist.

Shore N. Shore N. Curr Urol Rep. 2014 Jul;15(7):419. doi: 10.1007/s11934-014-0419-0. Curr Urol Rep. 2014. PMID: 24817261

3

Combined advanced prostate cancer treatments: are they additive?

Srivastava A, Shore ND. Srivastava A, et al. Among authors: shore nd. Nat Rev Urol. 2021 Jun;18(6):325-326. doi: 10.1038/s41585-021-00459-z. Nat Rev Urol. 2021. PMID: 33758370 No abstract available.

4

Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.

Jazayeri SB, Srivastava A, Shore N. Jazayeri SB, et al. Curr Opin Urol. 2022 May 1;32(3):283-291. doi: 10.1097/MOU.0000000000000984. Curr Opin Urol. 2022. PMID: 35552309 Review.

5

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer.

Jazayeri SB, Cooley LF, Srivastava A, Shore N. Jazayeri SB, et al. Eur Urol Open Sci. 2022 Sep 28;45:38-40. doi: 10.1016/j.euros.2022.05.015. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36186607 Free PMC article.

6

Influencing Best Practices for Genomic and Germline Testing in Urology.

Shore N, Scott TA, Srivastava A, Grove R, Thompson A, Tierno MB, Haberberger J. Shore N, et al. Urol Pract. 2023 Nov;10(6):648-654. doi: 10.1097/UPJ.0000000000000454. Epub 2023 Sep 26. Urol Pract. 2023. PMID: 37647173

7

Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.

Efstathiou JA, Morgans AK, Bland CS, Shore ND. Efstathiou JA, et al. Among authors: shore nd. Cancer Treat Rev. 2024 Jan;122:102630. doi: 10.1016/j.ctrv.2023.102630. Epub 2023 Sep 27. Cancer Treat Rev. 2024. PMID: 38035646 Free article. Review.

8

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.

Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Hussain M, et al. Among authors: shore nd. JAMA Oncol. 2024 May 9. doi: 10.1001/jamaoncol.2024.0591. Online ahead of print. JAMA Oncol. 2024. PMID: 38722620

9

Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?

Shore ND. Shore ND. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):1-6. doi: 10.1038/pcan.2012.23. Epub 2012 Jul 3. Prostate Cancer Prostatic Dis. 2013. PMID: 22751145 Review.

10

New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.

Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. Shore ND, et al. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7-15. doi: 10.1038/pcan.2012.25. Epub 2012 Jul 3. Prostate Cancer Prostatic Dis. 2013. PMID: 22751146 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page